Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01267266 · ClinicalTrials.gov registry record · Phase 2
Saracatinib in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01267266: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01267266 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01267266, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG saracatinib
- OTHER hydrocortisone/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01267266
The ClinicalTrials.gov registry entry for NCT01267266 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which saracatinib is the first listed.
NCT01267266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01267266 about?
NCT01267266 is a clinical study titled "Saracatinib in Treating Patients With Prostate Cancer". This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01267266?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2010-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01267266?
The interventions under investigation include: saracatinib (DRUG), hydrocortisone/placebo (OTHER).
Who is sponsoring clinical trial NCT01267266?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.